Indaptus Therapeutics Reports Q1 Loss and Financing Plans

Introduction

INDAPTUS THERAPEUTICS INC (NASDAQ: INDP) is a clinical-stage biotechnology company developing immunotherapies that leverage attenuated, non-pathogenic gram-negative bacteria to activate both innate and adaptive immune pathways. The company focuses on treatments for oncology and viral infections through its Decoy platform, which has generated a portfolio of 34 issued or granted patents worldwide.

Corporate Structure and Leadership

Indaptus Therapeutics is incorporated in Delaware and trades under the ticker INDP on the Nasdaq. The executive team brings decades of experience in drug development and business operations:

• Jeffrey A. Meckler, Chief Executive Officer: Over 30 years in healthcare leadership, including CEO roles at Intec Pharma and Cocrystal Pharma, with a background in strategic planning and corporate finance at Pfizer.
• Michael J. Newman, Ph.D., Chief Scientific Officer: Founder of the Decoy technology; more than 35 years in oncology drug discovery and early development in academia and industry.
• Walt A. Linscott, Chief Operating Officer: Three decades in life sciences business development, operations, and regulatory affairs; previously Chief Business Officer at Intec Pharma and held General Counsel roles at multiple biotech firms.

Recent Developments

On May 14, 2025, Indaptus reported its first quarter 2025 financial results: research and development expenses rose to $2.8 million from $1.6 million a year earlier, while general and administrative expenses declined to $1.8 million from $2.4 million. The company reported a loss per share of $0.32 compared to $0.45, and held cash and cash equivalents of $3.9 million as of March 31, 2025, down from $5.8 million at year-end 2024. Net cash used in operating activities increased to $5.0 million from $3.9 million, offset in part by $3.2 million of financing proceeds.

On June 13, 2025, a preliminary proxy (Form PRE 14A) was filed to seek stockholder approval at a Special Meeting scheduled for July 25, 2025, authorizing a private placement of convertible notes and warrants in compliance with Nasdaq rules. Two days later, on June 15, 2025, the company submitted a Form D to the SEC, indicating an exempt offering of securities to raise additional capital.

In October 2024, Indaptus entered a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with the PD-1 inhibitor tislelizumab. The Phase 1 trial of Decoy20 began in December 2022, with the first patient dosed in March 2023. Cohort data presented at scientific meetings include:

• March 2024 (Second Cohort): Broad immune activation across tumor types was reported.
• May 2024 (Weekly-Dose Cohort): No new treatment-related adverse events were observed.
• September 2024 (Higher Dose Expansion): An escalated weekly dosing regimen was initiated.

Patent allowances in China, Japan, and Israel, announced in November 2024, extend coverage for Decoy compositions targeting chronic hepatitis B and HIV infections. At the BIO International Convention from June 1–4, 2025, CEO Jeffrey Meckler discussed Decoy20’s mechanism and regulatory considerations alongside FDA Commissioner Martin Makary.

Financial and Strategic Analysis

As of June 23, 2025, INDP shares are trading at $0.57, reflecting a 111.03% intraday increase on volume of 53,517,173. The 52-week trading range spans $0.27 to $2.421, with an intraday market capitalization of approximately $4.33 million. Key metrics from Yahoo Finance include:

• Beta (5Y Monthly): 1.12
• EPS (TTM): –1.48
• Net Income (TTM): –$15.75 million
• Total Cash (MRQ): $3.89 million
• Total Debt/Equity (MRQ): 2.13%

The cash burn of $5.0 million in Q1 suggests operational funding needs may arise in the second quarter of 2025 absent further financing. The company has pursued equity and warrant offerings, including a $2.135 million registered direct offering in November 2024 and ongoing private placements. Strategic partnerships, such as the BeiGene supply agreement, support combination-therapy development while patent expansions address infectious-disease markets.

Market Position and Industry Context

Indaptus operates in the immuno-oncology and antiviral sectors, where checkpoint inhibitors and personalized cell therapies are prevalent. Its Decoy platform offers an antigen-agnostic approach designed for broad accessibility and intravenous administration. By targeting pathogen-associated molecular patterns (PAMPs) such as LPS, Indaptus aims to engage multiple receptors (TLR4, NOD, STING, RIG-I) and elicit coordinated immune responses. The company’s Phase 1 program enrolls patients across eight sites, and the planned Decoy20–tislelizumab combination cohort may position Indaptus alongside established PD-1 therapies. Within a regulatory environment that is currently under review, Indaptus’ bacterial-based immunotherapy represents a distinct approach in the biotechnology landscape.

TL;DR

On May 14, 2025, Indaptus Therapeutics reported $3.9 million in cash and a per-share loss of $0.32, with operating burn of $5.0 million. A July 25, 2025 special stockholder meeting is set to approve a private placement of notes and warrants, following a June 20, 2025 SEC Form D filing for an exempt securities offering. Decoy20’s Phase 1 trial continues, with a combination arm alongside BeiGene’s tislelizumab expected in H2 2025. Cash runway extends into Q2, and additional capital raises will be required to sustain operations and advance the pipeline.